Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$329,769.00
Award Year:
2013
Program:
STTR
Phase:
Phase II
Contract:
W81XWH-12-C-0183
Award Id:
n/a
Agency Tracking Number:
A2-5435
Solicitation Year:
2012
Solicitation Topic Code:
A12a-T027
Solicitation Number:
2012.A
Small Business Information
2213 Evening Sun Road, Nazareth, PA, 18064-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
962757584
Principal Investigator:
GarryMorefield
President
(610) 573-9620
garry.morefield@vaxform.com
Business Contact:
GarryMorefield
President
(610) 573-9620
garry.morefield@vaxform.com
Research Institute:
Purdue University
Harm HogenEsch
624 Harrison Street
West Lafayette, IN, 47907-
(765) 496-3487

Abstract
A vaccine to protect against diseases resulting from infection with Streptococcus pyogenes is under development. This vaccine utilizes a recombinant fusion protein (SpeAB) comprising of genetically detoxified SpeA, a secreted toxin, and SpeB, a surface bound and secreted cysteine protease. During phase I investigations a lead vaccine formulation was determined by optimization of critical parameters such as buffer, pH, stabilizer, and adjuvant interactions. Potency studies in mice demonstrated significantly greater induction of an antigen-specific IgG immune response to the vaccine than antigen alone. Additionally, the antibodies produced were functional at neutralization of wild type SpeA toxin. These results demonstrate that the SpeAB vaccine developed during the phase I investigation has great potential to provide protection against diseases resulting from infection by Streptococcus pyogenes. For phase II development of the vaccine the overall goal is to complete non-clinical safety studies in preparation of movement into clinical trials. To achieve this goal technical objectives including optimization of assays for antigen characterization, stability, and potency, development of cGMP scalable processes for fermentation and purification of SpeAB, and correlation of SpeAB potency with formulation stability will be investigated.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government